116.20 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 115.52 |
| Open | 116.31 |
| Bid | 116.00 x 800 |
| Ask | 116.18 x 3200 |
| Day's Range | 115.28 - 121.90 |
| 52 Week Range | 53.21 - 133.96 |
| Volume | 630,233 |
| Avg. Volume | 295,166 |
| Market Cap | 5.453B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
COPENHAGEN, Denmark, Aug. 14, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address significant unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate the ACcomplisH Trial, a global phase 2 trial designed to evaluate the safety and efficacy of TransCon CNP in children with achondroplasia. “With the phase 2 ACcomplisH Trial, we aim to demonstrate that once-weekly TransCon CNP, which provides continuous exposure to CNP, is a potential therapeutic option for children with achondroplasia,” said Jonathan Leff, M.D., Chief Medical Officer of Ascendis Pharma.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that the company will host an R&D Day for the investment community on Wednesday, June 26, 2019 in New York City. The event will feature an update on the company’s three endocrinology rare disease programs, including detailed data on the TransCon hGH phase 3 heiGHt and fliGHt Trials, updates on the TransCon PTH and TransCon CNP programs, an introduction to the commercial organization, and an introduction of the oncology vision, strategic goals and potential product candidates, with presentations from an outside oncology expert and Ascendis senior management. If you are a member of the investment community and would like to attend, please send an email to joshua.flax@westwicke.com to receive additional information.
– Continued execution of global endocrinology rare disease programs, following validation of TransCon™ platform in phase 3 heiGHt Trial – – R&D Day on June 26 to feature.
NEW YORK, NY / ACCESSWIRE / May 30, 2019 / Ascendis Pharma A/S (NASDAQ: ASND ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 30, 2019 at 4:30 PM Eastern ...
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced preliminary results from the phase 3 fliGHt Trial of TransCon Growth Hormone (hGH). The results indicated treatment with TransCon hGH was safe and well-tolerated in subjects with pediatric growth hormone deficiency (GHD) who were previously treated with commercially-available daily growth hormone therapies.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will hold a conference call and live webcast on Thursday, May 30, 2019 at 4:30 p.m. Eastern Time (ET) to review its first quarter 2019 financial results and provide a business update. A live webcast of the conference call will be available on the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
COPENHAGEN, Denmark, April 24, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
– Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated – – Phase 3 heiGHt Trial results showcase potential of TransCon™.
NEW YORK, NY / ACCESSWIRE / April 3, 2019 / Ascendis Pharma A/S Sponsored ADR (NASDAQ: ASND ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 3, 2019 ...
COPENHAGEN, Denmark, March 27, 2019 -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced a study evaluating impact of hypoparathyroidism (HP) on patients in a poster at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. The study found that, despite treatment with current therapies, 100 percent of patients experienced physical impact, psychological impact, and interference with daily life, reflecting a substantial illness burden from HP. “I have lived with HP for over 25 years and have personally experienced how this debilitating disease affects all areas of life - physical, emotional and social,” said Deb Murphy, President of the HypoPARAthyroidism Association, Inc. “This study highlights that currently available therapies are still not enough.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced top-line results from its pivotal phase 3 heiGHt Trial were presented at the Endocrine Society’s annual meeting, ENDO 2019, in New Orleans. Trial results demonstrated that TransCon Growth Hormone (hGH) administered once-weekly to children with pediatric growth hormone deficiency (GHD) had comparable safety and tolerability to daily Genotropin®, with a significantly greater increase in annualized height velocity over the one-year study period.
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
HENDERSON, NV / ACCESSWIRE / March 6, 2019 / Cannabis research firm, ArcView, sees North American legal pot sales reaching $22 billion by 2021 and $57 billion worldwide by 2027. So, it's little surprise ...
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransConTM technology to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,166,667 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $120.00 per ADS. All of the ADSs are being offered by Ascendis. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 625,000 ADSs at the public offering price, less the underwriting commissions.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical needs, today announced that it has commenced an underwritten public offering of $400,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of ADSs at the public offering price, less the underwriting commissions.
COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address unmet medical needs, today announced positive top-line results from the phase 3 heiGHt Trial, a randomized, open-label, active-controlled trial that compared once-weekly TransCon Growth Hormone (hGH) to a daily growth hormone (Genotropin®) in children with pediatric growth hormone deficiency (GHD). The trial met its primary objective, demonstrating that TransCon hGH was observed to be non-inferior and, additionally, superior to the daily hGH on the primary endpoint of annualized height velocity (AHV) at 52 weeks.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon CNP, a long-acting prodrug of C-type natriuretic peptide (CNP) in development for children with achondroplasia. Achondroplasia is the most common form of dwarfism and there are no FDA-approved therapies for this condition.
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration for initiation of PaTH Forward, a global phase 2 trial designed to evaluate the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism (HP). The trial will also evaluate a titration regimen for the complete withdrawal of standard of care (i.e., active vitamin D and calcium supplements).
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant unmet medical needs, today introduced Vision 3x3, the company’s strategic roadmap through 2025 to achieve sustainable growth, at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. “With the clinical validation of our three endocrinology rare disease product candidates, we have built a strong foundation to establish Ascendis as a leading rare disease company,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.
Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the company will participate in an upcoming investor conference. A live webcast of the event will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives.
- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent,.